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ABSTRACT
Background: Pirfenidone is an oral antifibrotic agent
that has been shown to reduce the decline in lung
function in patients with idiopathic pulmonary fibrosis
(IPF). We performed an integrated analysis of safety
data from five clinical trials evaluating pirfenidone in
patients with IPF.
Methods: All patients treated with pirfenidone in the
three multinational Phase 3 studies (CAPACITY (studies
004 and 006), ASCEND (study 016)) and two ongoing
open-label studies (study 002 and study 012 (RECAP))
were included in the analysis. Safety outcomes were
assessed during the period from the first dose until
28 days after the last dose of study drug.
Results: A total of 1299 patients were included in the
analysis. The cumulative total exposure to pirfenidone
was 3160 person exposure years (PEY). The median
duration of exposure was 1.7 years (range 1 week to
9.9 years), and the mean (±SD) daily dose was 2053.8
(±484.9) mg. Gastrointestinal events (nausea (37.6%),
diarrhoea (28.1%), dyspepsia (18.4%), vomiting
(15.9%)) and rash (25.0%) were the most common
adverse events; these were generally mild to moderate
in severity and without significant clinical
consequence. Elevations in alanine aminotransferase or
aspartate aminotransferase greater than three times the
upper limit of normal occurred in 40/1299 (3.1%)
patients (adjusted incidence, 2.3 per 100 PEY).
Elevations were generally transient and reversible with
dose modification or discontinuation.
Conclusions: A comprehensive analysis of safety
outcomes in a large and well-defined cohort of 1299
patients with IPF who were followed prospectively for
up to 9.9 years demonstrated that long-term treatment
with pirfenidone is safe and generally well tolerated.
Trial registration numbers: NCT00287716,
NCT00287729, NCT00662038, NCT01366209.
BACKGROUND
Pirfenidone is a novel oral antifibrotic agent
that is approved for the treatment of
idiopathic pulmonary fibrosis (IPF)—a
chronic, progressive, diffuse parenchymal
lung disease of unknown aetiology charac-
terised by irreversible declines in lung func-
tion and exercise capacity.1
The clinical efficacy and safety of pirfeni-
done in patients with IPF have been demon-
strated in three multinational, randomised,
double-blind, placebo-controlled, Phase 3
trials and one randomised, double-blind,
placebo controlled, Phase 3 trial conducted
in Japan.2–4 Clinical efficacy data from the
multinational Phase 3 trials provided evi-
dence of a meaningful treatment benefit on
multiple measures of disease status, including
forced vital capacity (FVC), 6-minute walking
distance (6MWD) and progression-free sur-
vival. Gastrointestinal and skin-related events
were the most commonly reported adverse
events; these were generally mild to
KEY MESSAGES
▸ These findings represent a comprehensive ana-
lysis of safety outcomes in a large and well-
defined cohort of 1299 patients with idiopathic
pulmonary fibrosis treated with pirfenidone.
▸ During this long-term, prospective follow-up of
up to 9.9 years, pirfenidone was safe and gener-
ally well tolerated.
▸ Gastrointestinal and skin-related events were
among the most common adverse events and
were generally mild-to-moderate in severity and
responsive to dose modification.
▸ Elevations of aminotransferases typically
occurred within the first 6 months of treatment
and were generally transient, reversible with
dose modification or discontinuation and
without clinical sequelae.
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moderate in severity and rarely resulted in treatment dis-
continuation. In a pooled analysis of outcomes in the
three multinational trials, there were fewer deaths due
to any cause and fewer deaths related to IPF in the pirfe-
nidone group compared with placebo.3
A subsequent integrated analysis of safety in 789
patients treated with pirfenidone in either of two Phase 3
studies (studies 004 and 006 (CAPACITY)) and/or one of
two open-label studies (study 002 and study 012
(RECAP)) demonstrated that treatment with pirfenidone
for up to 7.7 years was safe and generally well tolerated.5
Consistent with prior observations, gastrointestinal and
skin-related events were common but were generally mild
to moderate in severity and rarely led to treatment dis-
continuation. Elevations in alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) greater than
three times the upper limit of normal (ULN) occurred in
2.7% of patients; however, all were transient, reversible
with dose modification and without clinical sequelae.
To further evaluate the long-term safety and tolerabil-
ity of pirfenidone, we performed a comprehensive ana-
lysis of safety outcomes in the integrated population
from five clinical trials evaluating pirfenidone in patients
with IPF, including three Phase 3 multinational trials
and two long-term open-label studies. The present
report includes data from an additional pivotal trial
(ASCEND) and a substantially increased cumulative
total duration of exposure to pirfenidone compared
with the previously published integrated safety analysis.
METHODS
Study subjects
All patients randomised to treatment with pirfenidone
in the Phase 3 multinational studies (CAPACITY (studies
004 and 006), ASCEND (study 016)) and all patients
receiving at least one dose of pirfenidone in either of
two ongoing open-label studies (study 002 and study 012
(RECAP)) formed the integrated population. Study 002
is an open-label compassionate use study in the USA;
study 012 is an open-label extension study evaluating pir-
fenidone in patients who completed any one of the
three phase 3 multinational studies.
Eligibility criteria for the Phase 3 multinational studies
have been previously described (see supplementary
material, table S1).2 3 All patients who completed the
final study visit in the Phase 3 multinational studies were
eligible for enrolment in study 012. The original eligibil-
ity criteria for study 002 included a diagnosis of either
IPF or secondary pulmonary fibrosis; secondary pulmon-
ary fibrosis was eliminated as a diagnostic eligibility cri-
terion in Protocol Amendment 1 (15 December 2003).
Study design
All patients who met the criteria for enrolment in the
Phase 3 multinational studies were randomised to treat-
ment with pirfenidone or placebo. In study 004, patients
were randomly assigned (2:1:2) to one of three groups:
pirfenidone 2403 mg/day, pirfenidone 1197 mg/day or
placebo. In studies 006 and 016, patients were randomly
assigned (1:1) to treatment with pirfenidone 2403 mg/
day or placebo. Study drug was administered orally with
food in three equally divided daily doses and escalated
to the full dose during a 2-week dose titration period in
all three studies. Patients were treated for a minimum of
72 weeks in studies 004 and 006 and for 52 weeks in
study 016.
In study 012, all eligible patients were treated with oral
pirfenidone 2403 mg/day administered according to the
same schedule as in the Phase 3 studies. All patients
were required to complete a 2-week dose escalation
period, regardless of prior treatment assignment in the
Phase 3 studies. In study 002, patients who enrolled
prior to protocol amendment 2 (15 September 2005)
received pirfenidone 40 mg/kg/day (maximum of
3600 mg/day) administered orally in three equally
divided daily doses following a 2-week dose escalation
period. Patients who enrolled after the protocol amend-
ment were treated with a target maintenance dose of
2403 mg/day.
Physical examination and routine clinical laboratory
tests were performed at prespecified intervals in all five
studies. A directed medical history, including a review of
adverse events, concomitant medications, hospitalisa-
tions and compliance with the assigned treatment
regimen, was conducted at each study visit.
Statistical analysis
All analyses were conducted using data from the inte-
grated population as of the interim data cut-off date of
17 January 2014. Demographic and baseline character-
istics are summarised descriptively for the integrated
population as well as for the pooled pirfenidone
2403 mg/day and placebo groups from the multi-
national Phase 3 trials.
The total duration of exposure to study drug is
defined as the time between the first and last dose of
study drug. For patients who were treated with pirfeni-
done in the Phase 3 studies and subsequently enrolled
in the open-label extension study (study 012), total dur-
ation of exposure is based on the time from the first
dose of study drug in the Phase 3 study to the last dose
of study drug in the open-label extension study at the
interim data cut-off date (17 January 2014). The cumula-
tive total exposure is expressed as person exposure years
(PEY); one PEY is equal to one patient exposed to study
drug for 1 year. The mean daily dose of study drug was
calculated over the full duration of use, excluding the
2-week titration period.
Treatment-emergent adverse events (TEAEs) are
defined as adverse events with an initial onset or worsen-
ing following the first dose and within 28 days after the
last dose of study drug. The crude and adjusted inci-
dence rates of treatment-emergent death, defined as
death due to any cause between the first dose and
28 days after the last dose of study drug, are summarised
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for the integrated population and by treatment assign-
ment in the Phase 3 studies. The crude incidence was
adjusted for differences in duration of exposure by using
person-time in the denominator. The adjusted incidence
of mortality is reported as deaths per 100 PEY (number
of deaths divided by the total PEY for the group, multi-
plied by 100).
Analyses of liver-related outcomes included all patients
who had at least 4 weeks of exposure to study drug.
Crude and adjusted incidence rates are summarised for
the integrated population and by treatment assignment
in the Phase 3 studies. The crude incidence was calcu-
lated as the number of events divided by the total
number of patients exposed to study drug. The adjusted
incidence rate was calculated as the number of events
divided by the total PEY for the group.
All study participants provided written informed
consent, and the protocol for each study was approved
by the ethics committee or institutional review board at
each participating institution.
RESULTS
The integrated population included a total of 1299
patients; of these, 710 (54.7%) were initially treated with
pirfenidone in the Phase 3 studies (study 004, n=261;
study 006, n=171; study 016, n=278), 506 (39.0%) were
treated with placebo in the Phase 3 studies and initiated
treatment with pirfenidone in study 012 and 83 (6.4%)
initiated treatment with pirfenidone in study 002
(figure 1).
Demographics and baseline characteristics in the inte-
grated patient population are summarised in table 1.
The majority of patients were Caucasian (94.6%) and
male (74.5%). A total of 97 (7.5%) and 210 (16.2%)
patients in the integrated population had baseline
values for FVC and carbon monoxide diffusing capacity
(DLCO), respectively, that were below the minimum
criteria for enrolment in the original Phase 3 CAPACITY
studies, including 79 (6.1%) patients who had baseline
DLCO values below 30%, the minimum criterion for
enrolment in the ASCEND study (see online supplemen-
tary material, figure S1).
Overall exposure to pirfenidone is summarised in
table 2. The cumulative total exposure to pirfenidone
was 3160 PEY. The median duration of exposure was
1.7 years (range 1 week to 9.9 years), and the mean
(±SD) daily dose was 2053.8 (±484.9) mg. A total of 545
(42%) patients received pirfenidone for ≥2 years and
325 (25%) patients received pirfenidone for ≥4 years.
The majority of patients (964 (74.2%)) received a mean
daily dose between 1800 and 2600 mg.
Consistent with prior observations in the pirfenidone
and placebo groups in the Phase 3 clinical trials,
almost all patients in the integrated population experi-
enced at least one TEAE (see online supplementary
material, table S2). A total of 495 (38.1%) patients in
the integrated population discontinued treatment due
to an adverse event, compared with 91 (14.6%) and 60
(9.6%) patients in the pooled pirfenidone and placebo
groups in the Phase 3 trials. When adjusted for differ-
ences in duration of exposure, the rate of TEAEs in
the integrated population was consistent with the rates
in the Phase 3 trials. The most common adverse event
leading to treatment discontinuation in the integrated
population was IPF (11.5%); the only other events that
led to discontinuation in >1% of patients were nausea
(1.7%), rash (1.5%) and respiratory failure (1.3%).
The most common adverse events are presented in
table 3. Gastrointestinal events (nausea (37.6%), diar-
rhoea (28.1%), dyspepsia (18.4%), vomiting (15.9%))
and rash (25.0%)) were among the most commonly
reported adverse events in the integrated population;
these were generally mild to moderate in severity and
rarely led to treatment discontinuation (table 4).
Additionally, the incidence of gastrointestinal and skin-
Figure 1 Study profile.
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related events was similar to the observed incidence
among patients treated with pirfenidone in the Phase 3
trials, suggesting that the risk of such events does not
increase with prolonged exposure. Respiratory adverse
events, including cough, dyspnoea and IPF, were more
common in the integrated population than in the
pooled pirfenidone and placebo groups in the Phase 3
trials—a finding that is consistent with expectations in a
population with a chronic progressive respiratory disease
over a long duration of observation.
Serious adverse events were reported by 639 (49.2%)
patients in the integrated population, compared with
168 (27.0%) and 178 (28.5%) patients, respectively, in
pooled pirfenidone and placebo groups in the Phase 3
trials. When adjusted for the longer duration of expos-
ure, the rate of serious adverse events in the integrated
population (49.8 per 100 PEY) was comparable to the
observed rates in the pooled pirfenidone and placebo
groups in the Phase 3 trials (41.7 and 44.2 per 100 PEY,
respectively). The most common serious adverse events
in the integrated population were worsening IPF
(17.5%), pneumonia (7.9%), respiratory failure (3.2%),
atrial fibrillation (2.8%) and bronchitis (2.7%). With the
exception of atrial fibrillation, which occurred in 0.6%
of patients in the pirfenidone and placebo groups in the
Phase 3 trials, the incidence of each of these events was
higher in the placebo group than in the pirfenidone
group in the Phase 3 trials (see online supplementary
material, table S3).
Analysis of liver chemistries in the integrated popula-
tion showed no evidence of an increased risk of liver
toxicity with longer durations of treatment. Elevations
in ALT or AST greater than three times the ULN
(>3×ULN) occurred in 3.1% of patients in the inte-
grated population, compared with 3.7% and 0.8%,
respectively, in the pooled pirfenidone and placebo
groups in the Phase 3 trials (see online supplementary
material, table S4). The adjusted incidence rate for
ALT or AST elevations >3×ULN was 2.3 per 100 PEY in
the integrated population, compared with 6.5 per 100
PEY in the pirfenidone group and 0.9 per 100 PEY in
the placebo group during the Phase 3 trials. Elevations
in aminotransferases were generally transient, reversible
with dose modification and without significant clinical
consequence. The Kaplan-Meier distribution for the
time to onset of ALT or AST elevations >3×ULN showed
that the majority of events occurred within the first
6 months of treatment (see online supplementary
Table 1 Demographics and baseline characteristics
Phase 3 trials‡
Characteristic*† Integrated population (N=1299) Pirfenidone (N=623) Placebo (N=624)
Age, years 68 (42–88) 68 (45–80) 68 (40–80)
Men, n (%) 968 (74.5) 463 (74.3) 465 (74.5)
Caucasian, n (%) 1229 (94.6) 592 (95.0) 590 (94.6)
FVC, % predicted 69.1 (22–127) 71.1 (46–123) 69.8 (47–138)
<50% predicted, n (%) 97 (7.5) 13 (2.1) 8 (1.3)
DLCO, % predicted 43.3 (10–81) 44.0 (25–81) 44.3 (21–170)
<35% predicted, n (%) 210 (16.2) 92 (14.8) 90 (14.4)
<30% predicted, n (%) 79 (6.1) 19 (3.0) 16 (2.6)
Diagnosis, n (%)
IPF 1297 (99.8) 623 (100) 624 (100)
Secondary pulmonary fibrosis§ 2 (0.2) 0 0
Supplemental oxygen, n (%) 375 (28.9) 155 (24.9) 150 (24.0)
Time since IPF diagnosis, years 1.9 (>0–10) 1.1 (>0–5) 1.1 (>0–4)
*Values are expressed as the median (range) unless otherwise indicated.
†Measured at the time of first dose of study drug.
‡CAPACITY (studies 004 and 006) and ASCEND (study 016).
§Study 002.
DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis.
Table 2 Extent of exposure to pirfenidone
Integrated population
(N=1299)
Duration of treatment, years
Median (range) 1.7 (>0 to 9.9)
>0 to <1 404 (31.1%)
1 to <2 350 (26.9%)
2 to <3 118 (9.1%)
3 to <4 102 (7.9%)
≥4 325 (25.0%)
Person exposure years (PEY)* 3160
Daily dose, mg†
Mean (SD) 2053.8 (484.9)
Median (range) 2270.4 (25–3600)
>0 to ≤1800 295 (22.7%)
>1800 to ≤2200 228 (17.6%)
>2200 to 2600 736 (56.7%)
>2600 19 (1.5%)
Missing 21 (1.6%)
*One PEY is the equivalent of one patient exposed to study drug
for 1 year; total PEY is the sum of the PEY of each patient.
†Calculated over the total duration of use, excluding the 2-week
titration period.
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material, figure S2). Elevations in aminotransferases
and/or serum bilirubin that occurred beyond 6–
12 months of first exposure to pirfenidone could typic-
ally be attributed to other causes. Liver-related serious
adverse events occurred in 1.0% of patients in the inte-
grated population, compared with 1.0% and 0.2%,
respectively, in the pooled pirfenidone and placebo
groups in the Phase 3 trials.
A total of 233 (17.9%) deaths occurred between the
first dose and 28 days after the last dose of study treatment
in the integrated population (adjusted incidence, 7.4 per
100 PEY). The adjusted incidence of treatment-emergent
death among the pooled treatment groups during the
Phase 3 trials was 3.7 per 100 PEY in the pirfenidone
group and 5.9 per PEY in the placebo group.
DISCUSSION
We performed a comprehensive analysis of safety out-
comes in a large and well-defined cohort of patients
with IPF who were treated with pirfenidone and followed
prospectively for up to 9.9 years (median 1.7 years; IQR
0.7–4.0 years). Our results provide further evidence that
long-term treatment with pirfenidone is safe and gener-
ally well tolerated. Consistent with previous reports,2–9
gastrointestinal and skin-related events were among the
most common adverse events; these were generally mild
to moderate in severity and responsive to dose modifica-
tion or other adverse event mitigation strategies.
Of note, study subjects in the Phase 3 trials and the
open-label extension study were instructed to take pirfe-
nidone with food and advised to avoid sun exposure and
to use sun block during treatment. Additionally,
protocol-defined dose modification guidelines for gastro-
intestinal and skin-related adverse events were employed
in the Phase 3 and open-label extension studies and sub-
sequently incorporated into the product label.10 11 The
generally transient nature of these events and the rela-
tively low incidence of treatment discontinuation due to
gastrointestinal or skin-related events over a longer dur-
ation of exposure provide further support for these
recommendations.
The crude incidence of serious adverse events
(unadjusted for differences in duration of exposure) was
higher in the integrated population compared with that
in the pooled pirfenidone and placebo groups in the
Phase 3 clinical trials. However, this difference was
driven largely by the increased incidence of worsening
IPF—an expected finding given the irreversible nature
of the disease and the long duration of observation.
Clinically significant elevations in aminotransferases
occurred in a lower proportion of patients in the inte-
grated population than in the pooled pirfenidone group
in the Phase 3 trials. Analysis of serial laboratory results
showed that these tended to occur within the first
6 months of treatment and were generally transient,
reversible and without clinical sequelae. However, in
light of the higher incidence of aminotransferase eleva-
tions in the pirfenidone group compared with placebo
in the Phase 3 trials, the recommendation in the
product labels to perform liver chemistry tests at
monthly intervals for the first 6 months of treatment
and at 3-month intervals thereafter remains consistent
with prudent medical management.10 11
Table 3 Treatment-emergent adverse events*
Phase 3 multinational trials‡
Integrated population (N=1299)† Pirfenidone (N=623) Placebo (N=624)
Duration of exposure, median (range), years 1.7 (>0, 9.9) 1.0 (>0, 2.3) 1.0 (>0, 2.3)
Treatment-emergent adverse event, %
Nausea 37.6 36.1 15.5
Cough 35.1 27.8 29.2
Dyspnoea 30.9 16.9 20.2
Upper respiratory tract infection 30.6 26.8 25.3
Idiopathic pulmonary fibrosis 29.3 13.0 19.9
Fatigue 28.2 26.0 19.1
Diarrhoea 28.1 25.8 20.4
Rash 25.0 30.3 10.3
Bronchitis 23.8 14.1 15.4
Headache 21.6 22.0 19.2
Nasopharyngitis 21.3 16.7 17.9
Dizziness 21.2 18.0 11.4
Dyspepsia 18.4 18.5 6.9
Vomiting 15.9 13.3 6.3
Weight decreased 15.6 10.1 5.4
Back pain 15.4 10.4 10.4
Anorexia 15.2 13.0 5.0
*Occurring in ≥15% of patients in the cumulative clinical database.
†Includes two patients in study 002 with a diagnosis of “pulmonary fibrosis.”
‡CAPACITY (studies 004 and 006) and ASCEND (study 016).
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The strengths of our study include the large and
well-defined study population the rigorous, prospective
collection of longitudinal safety data and the duration of
exposure to study drug of up to 10 years. To the best of
our knowledge, the cumulative total exposure of 3160
PEY represents the largest and longest experience to
date with any specific therapy in patients with IPF.
Additionally, the integrated population comprised
patients with a broad range of physiological impairment,
including those with baseline values for FVC and DLCO
that mandated exclusion from the Phase 3 clinical trials.
The study population is therefore broadly reflective of
the general population of patients with IPF, thereby
enhancing the generalisability of the findings.
The findings of our study should be interpreted in the
context of certain limitations. First, two of the five
studies included in the analysis were open-label studies
that did not include a parallel control group. Second,
while study eligibility was generally broad, patients with
certain comorbidities such as renal failure requiring dia-
lysis and severe hepatic impairment or those receiving
selected concomitant medications were excluded from
enrolment in the studies included in our analysis (see
online supplementary material, appendix 1). The extent
to which the findings are generalisable to patients with
these and other excluded comorbidities or to patients
taking medications that were prohibited during the clin-
ical trials, is therefore not known. Finally, clinical efficacy
outcomes, such as 6MWD, DLCO and dyspnoea, were
not assessed in the open-label studies. While serial mea-
sures of FVC were performed in these studies, the
absence of a control group precludes meaningful
interpretation of the results. Due consideration should
therefore be given to the limited availability of efficacy
data beyond 72 weeks in the assessment of the relative
benefits and risks associated with long-term pirfenidone
treatment.
CONCLUSION
A comprehensive analysis of safety outcomes in a large
and well-defined population of 1299 patients with IPF
Table 4 Gastrointestinal and skin-related adverse events of interest
Phase 3 multinational trials†
Integrated population (N=1299)* Pirfenidone (N=623) Placebo (N=624)
Nausea, %
Grade 3 TEAE 1.9 1.8 0.5
Grade 4 TEAE 0 0 0
TE SAE 0 0.5 0
Treatment discontinuation 1.7 1.1 0
Diarrhoea, %
Grade 3 TEAE 1.1 0.6 0
Grade 4 TEAE 0 0 0
TE SAE 0 0 0.2
Treatment discontinuation 0.2 0 0.3
Dyspepsia, %
Grade 3 TEAE 0.5 0.3 0.3
Grade 4 TEAE 0 0 0
TE SAE 0 0 0
Treatment discontinuation 0.2 0 0
Vomiting, %
Grade 3 TEAE 0.6 0.5 0
Grade 4 TEAE 0 0 0
TE SAE 0.2 0.2 0
Treatment discontinuation 0.3 0.3 0.2
Rash, %
Grade 3 TEAE 0.5 0.6 0.2
Grade 4 TEAE 0 0 0
TE SAE <0.1 0.2 0
Treatment discontinuation 2.2‡ 1.4 0
Photosensitivity reaction, %
Grade 3 TEAE 0.5 0.8 0.2
Grade 4 TEAE 0 0 0
TE SAE 0 0.2 0
Treatment discontinuation 0.5 0.6 0.2
*Median duration of exposure, 1.7 years.
†Median duration of exposure, 1.1 years.
‡Includes rash (1.5%), erythematous rash (0.2%), generalised rash (0.3%), papular rash (0.2%), pruritic rash (<0.1%).
TEAE, treatment-emergent adverse event; TE SAE, treatment-emergent serious adverse event.
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who received pirfenidone for up to 9.9 years demon-
strated that long-term treatment with pirfenidone is safe
and generally well tolerated.
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